An update on the 2020 annual meeting in Beijing, China

20 March 2020 - Based on the balance of the evidence before the Board, and with the strong support of our ...

Read more →

Hansoh Pharma’s Ameile (almonertinib) receives marketing authorisation in China for second-line treatment for patients with EGFR T790 mutation non-small cell lung cancer

19 March 2020 - Hansoh Pharmaceutical Group announced that the National Medical Products Administration has granted marketing authorisation for Ameile ...

Read more →

Chinese official warns against U.S. effort to limit foreign medicine supplies

17 March 2020 - A Chinese official on Monday warned that a push by the White House to reduce U.S. ...

Read more →

Reliance on China for medicines an emergency

16 March 2020 - The United States has declared a national emergency as a result of the spread of COVID-19. ...

Read more →

Coronavirus spurs U.S. efforts to end China’s chokehold on drugs

11 March 2020 - The Trump administration says the U.S. is too dependent on China for vital drugs. But it’s unclear ...

Read more →

Global companies expand the reach of their cancer drugs in China

10 March 2020 - While much of the world is understandably focused on the new coronavirus’s emergence in China, three ...

Read more →

Erbitux approved for first-line use in China in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

2 March 2020 - Approval is for Erbitux in combination with platinum-based therapy with 5-fluorouracil for the first-line treatment of R/M ...

Read more →

China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

14 February 2020 - This marks the first approval for a Tecentriq-based therapy in China, less than a year after the ...

Read more →

NRDL list could lead to increased access to innovative drugs in China

27 January 2020 - China has started to regularly update its National Reimbursement Drug List which could lead to new opportunities ...

Read more →

Roche wins approval for cancer drug Kadcyla in fast-growing China market

23 January 2020 - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another ...

Read more →

China drives down drug prices with bulk buy bidding

18 January 2020 - Pharma giants that used to profit from off-patent drugs forced to compete with local generic makers. ...

Read more →

Lokelma approved in China for the treatment of adult patients with hyperkalaemia

6 January 2020 - Patients in China will benefit from Lokelma’s rapid reduction of potassium in the blood and the ...

Read more →

China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies

27 December 2019 - Second BeiGene discovered drug to receive regulatory approval, first in China. ...

Read more →

AstraZeneca’s triple-combination therapy approved in China for patients with COPD

23 December 2019 - First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device in China. ...

Read more →

China’s cancer patients hit by new law on experimental drug treatments not approved by government

11 December 2019 - The law came into effect on December 1 and forbids pharmaceutical firms giving patients drugs from unapproved ...

Read more →